PH

(redirected from Philadelphia chromosome)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Encyclopedia, Wikipedia.

PH

The two-character ISO 3166 country code for PHILIPPINES.
References in periodicals archive ?
Data from the DASISION trial demonstrated that newly diagnosed patients with Philadelphia chromosome positive CML in chronic phase who received dasatinib attained higher and faster molecular and confirmed complete cytogenetic response rates by 12 months compared to imatinib.
Although a number of previous studies had shown chromosomal abnormalities in human cancer, the Philadelphia chromosome was the first documentation of a bona fide genetic signature of malignancy, and this discovery led Dr.
Bosulif is intended for patients with chronic, accelerated or blast phase Philadelphia chromosome positive CML who are resistant to or who cannot tolerate other therapies, including imatinib.
Furthermore, imatinib is approved for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy, adult patients with relapsed or refractory Ph+ ALL as monotherapy, adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements, adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFR alpha rearrangement and the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery.
Data from the largest clinical trial in newly diagnosed patients with Philadelphia chromosome positive (Ph+) chronic myeloid leukaemia (CML) demonstrate the longest overall survival observed to date in this disease area.
A key discriminating cytogenetic abnormality is the Philadelphia chromosome.
Ph-like ALL is named after a chromosomal rearrangement known as the Philadelphia chromosome, which is associated with another subtype of ALL.
Tasigna(R) (nilotinib) is now available in the UK as a new option to treat adult patients who are intolerant or resistant to previous therapies for Philadelphia chromosome positive (Ph+) chronic myeloid leukaemia (CML).
Submission Accepted for Bosutinib for Patients with Newly Diagnosed Philadelphia Chromosome Positive Chronic Myeloid Leukemia
Together, Penn and Novartis will build a first-of-its-kind Center for Advanced Cellular Therapies (CACT) on the Penn campus in Philadelphia -- a venture which will bring full circle the 1960 discovery of the Philadelphia chromosome, the first description of a chromosome abnormality that causes cancer.
Major cytogenetic response is defined as complete (no signs of Philadelphia chromosome positive [Ph+] cells in the bone marrow) plus partial (less than 35% of Ph+ cells in the bone marrow) cytogenetic responses.
In November 2008, CytRx announced that bafetinib demonstrated clinical responses in patients with CML in an international, open-label Phase 1 dose-ranging clinical trial conducted in patients with CML and other leukemias that have a certain mutation called the Philadelphia Chromosome (Ph+) and are intolerant of or resistant to Gleevec[R] and, in some cases, second-line tyrosine kinase inhibitors such as dasatinib and nilotinib.

Full browser ?